37th week of 2022 patent applcation highlights part 10 |
Patent application number | Title | Published |
20220288118 | DEPLETION REGIMES FOR ENGINEERED T-CELL OR NK-CELL THERAPY - The invention provides method of depleting endogenous T-cells or NK-cells to facilitate propagation or survival of engineered T-cells introduced into a subject for a therapeutic purpose. The depletion regime involves a co-administration of an immunotherapeutic agent against T-cells and an immunotherapeutic agent that inhibits CD47 interaction with NK-cells. The immunotherapeutic agent against T-cells or NK-cells binds to an antigen on T-cells or NK-cells effecting depletion of the T-cells or NK-cells, which depletion is promoted by the immunotherapeutic agent inhibiting CD47-SIRPα interaction. The genetically engineered T-cells or NK-cells can have a variety of genetic modifications such as a chimeric antigen receptor that targets the T-cells to a target cell. | 2022-09-15 |
20220288119 | THIRD PARTY VIRUS-SPECIFIC T CELL COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME IN ANTI-VIRAL PROPHYLAXIS - The present disclosure includes compositions and methods for preventing viral infection and/or preventing reactivation of a latent virus in a subject. The methods involve prophylactically administering at least one antigen-specific T cell line from a third party donor and/or a donor minibank and/or a donor bank to a subject. The subject may be a patient who has received a transplant (e.g., a tissue, solid organ, or bone marrow transplant) or who is in need of such a transplant, or is immunosuppressed or in need of immunosuppressive therapy. | 2022-09-15 |
20220288120 | METHOD FOR PRODUCING ENGINEERED TIRC7 SPECIFIC T-REGULATORY CELLS (TREGS) - The present invention pertains to an improved composition of cells enriched in regulatory T (Treg) cells and a method for producing the same. In particular, the invention provides a novel strategy to produce such compositions of cells enriched in Tregs, comprising identifying, isolating and expanding cells positive for T cell immune response cDNA 7 (TIRC7) protein as well as CD25. The compositions enriched in Tregs prepared in accordance with the methodology of the invention are particularly useful for medical applications such as the treatment of immunological disorders and infectious diseases. Thus, the present disclosure offers a promising novel treatment approach as a cell-based therapy for patients suffering from immunological disorders, such as allergy, asthma, autoimmune disorders, graft versus host disease (GVHD), and transplantation graft rejection, or infectious diseases. | 2022-09-15 |
20220288121 | CELL CRYOPRESERVATION MEDIUM - Provided herein are cryopreservation compositions and methods for cells of any kind, including for cells for adoptive cell therapy that are off-the-shelf cells. The cells for cryopreservation may be expanding NK cells expressing chimeric antigen receptors. In specific cases, the cryopreservation media comprises a cryoprotectant, such as DMSO, glycerol or hydroxyethol starch; serum or a non-serum alternative, such as platelet lysate; and one or more cytokines that are either natural, modified, synthetic, or recombinant. | 2022-09-15 |
20220288122 | GENETICALLY ENGINEERED T CELLS WITH PTPN2 KNOCKOUT HAVE IMPROVED FUNCTIONALITY AND ANTI-TUMOR ACTIVITY - A population of genetically engineered T cells, comprising a disrupted protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene and optionally a disrupted TRAC gene, a disrupted β2M gene, and/or a disrupted CD70 gene. Also provided herein are methods for making such genetically engineered T cells and therapeutic uses thereof. | 2022-09-15 |
20220288123 | Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof - The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention targets CD19 and/or CD20 positive cells and can be used to treat CD19 and/or CD20 positive B-cell lymphoma, leukemia and other diseases. | 2022-09-15 |
20220288124 | CAR-T CELL COMPOSITIONS, METHODS OF USE THEREOF - Chimeric antigen receptor T cell (CARTs) compositions and methods of their use are provided. One embodiment provides a chimeric antigen receptor T cell composition including 8F8 chimeric antigen receptor T cells. Another embodiment provides a chimeric antigen receptor T cell composition including 6G11 chimeric antigen receptor T cells. Still another embodiment provide a chimeric antigen receptor T cell composition including 12D7 chimeric antigen receptor T cells. The disclosed CARTs can be used to treat cancer, for example hepatocellular carcinoma. | 2022-09-15 |
20220288125 | Nutritional Composition for Improving Sleep - A nutritional composition that includes from about 75% to about 95% of a first protein source that includes from about 85% to about 99% of protein by weight of the first protein source to provide an endogenous source of tryptophan in an amount between about 1% to about 6% of tryptophan by weight of the first protein source; and from about 0.5% to about 2% of a second protein source by weight of the nutritional composition, the second protein source consisting of an exogenous source of tryptophan such that the nutritional composition provides a ratio of tryptophan to large neutral amino acids in the range from about 0.080:1 to about 0.167:1. | 2022-09-15 |
20220288126 | ALKALIZED ORGANIC PHARMACEUTICAL OR NUTRACEUTICAL COMPOSITION - The invention relates to a pharmaceutical or nutraceutical composition comprising an alkalized organic substance selected from the group comprising proteins, carbohydrates, lipids, amino acids, vitamins, therapeutic agents and mixtures thereof. Such compositions are useful for treating a range of diseases and conditions. They also give rise to beneficial physiological effects such as, for example, increasing physical strength, muscle mass and endurance. | 2022-09-15 |
20220288127 | LYMPH NODE AS A SITE FOR TRANSPLANTATION, ORGANOGENESIS AND FUNCTION FOR MULTIPLE TISSUES AND ORGANS - The present invention relates to methods and compositions for transplanting non-lymphoid tissues into lymphoid organs. It may be used to cultivate organ tissues including for the purpose of supplementing or reconstituting organ function. Tissues that may be propagated in this manner include but are not limited to lung, kidney, thyroid, intestine, and brain. | 2022-09-15 |
20220288128 | MESENCHYMAL STEM CELL COMPOSITIONS - The present disclosure relates to compositions that comprise an enriched stromal vascular fraction, and methods of use thereof. | 2022-09-15 |
20220288129 | COMPOSITIONS FOR MONOCYTE AND MACROPHAGE POLARIZATION AND METHODS OF USE - Provided herein are methods and compositions for monocyte and macrophage polarization including methods for use in treating a disease or disorder. | 2022-09-15 |
20220288130 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF METABOLIC DISEASES AND DISORDERS - Provided are methods for increasing insulin sensitivity in subjects. In some embodiments, the method include administering to the subject an effective amount of a composition comprising a lipid bilayer, wherein the lipid bilayer is low in total phosphatidylcholine (PC) or has been treated to reduce total PC. Also provided are methods for diagnosing insulin sensitivity and/or a metabolic-related disorders, for preferentially targeting hepatocytes, for preferentially targeting liver macrophages and/or monocytes, for inhibiting development of insulin resistance, optionally insulin resistance associated with diabetes, for restoring gut epithelial homeostasis, for enhancing expression of a Foxa2 gene product in cells, for inhibiting Akt-1-mediated inactivation of Foxa2 biological activities, for increasing expression of VAMP7, miR-375, or both in epithelial cells, for enhancing sorting of miR-375 from intestinal epithelial cells to exosomes, for inhibiting hepatic AhR expression, and for inhibiting development of obesity in subjects in need thereof. | 2022-09-15 |
20220288131 | COMPOSITIONS AND METHODS OF TREATING VASCULAR DISEASES - The present invention generally relates to novel mesoderm-derived vascular progenitor cells (meso-VPCs) and methods of producing the meso-VPCs. The present invention also relates to methods of treating a vascular disease, such as critical limb ischemia, by administering the meso-VPCs into a subject. | 2022-09-15 |
20220288132 | METHOD FOR PREPARATION OF BLASTOCYST - Provided a method for preparing a blastocyst. The method includes culturing a fertilized egg in a culture medium containing bubbles containing a reducing gas. The reducing gas may contain at least one selected from the group consisting of hydrogen, carbon monoxide, nitrogen monoxide, and hydrogen sulfide. The bubbles may have an average particle size of from 10 nm to 1,000 nm. | 2022-09-15 |
20220288133 | COMPOSITIONS FOR THE TREATMENT OF CONDITIONS BY DERMAL FILLERS - The present disclosure relates to the treatment of diseases or conditions in a subject, including skin conditions or diseases, comprising applying to the skin of the subject a first composition comprising | 2022-09-15 |
20220288134 | COMPOSITION, SYSTEM AND METHOD FOR TREATING SKIN - A composition for wound healing and/or skin treatment comprises honey and a carbonate and/or bicarbonate salt. The salt is preferably capable of releasing CO | 2022-09-15 |
20220288135 | LIVE BIOTHERAPEUTIC COMPOSITIONS AND METHODS - Live biotherapeutic compositions and methods are provided for treatment, prevention, or prevention of recurrence of skin and soft tissue infections, such as mastitis and/or intramammary infections, for example, in cows, goats, sows, and sheep. Methods include decolonizing and durably replacing with a live biotherapeutic composition comprising a synthetic microorganism that may safely and durably replace an undesirable microorganism under dermal, mucosal, or intramammary conditions. | 2022-09-15 |
20220288136 | Compositions and Methods for Diagnosing Susceptibility to Autism Spectrum Disorder (ASD), Reducing the Likelihood of Developing ASD, and/or Treating ASD - The present invention provides compositions and methods for improving the quality of life for a subject, particularly a child, diagnosed with autism spectrum disorder (ASD). In preferred embodiments, a supplement composition comprising natural or naturally-derived ingredients is delivered to a subject in the form of a chocolate bar or other candy alongside administration of an antiviral medication. Advantageously, the composition and methods can improve the immune health of the subject, along with other signs and symptoms associated with ASD, infections and other immunocompromising conditions. | 2022-09-15 |
20220288137 | Bifidobacterium Longum Subsp. Infantis CCFM687 and Fermented Food and Application Thereof | 2022-09-15 |
20220288138 | Composition for Babies and Infants for Improving Memory Ability in Childhood - A problem of the invention is to provide a technique for improving memory ability in later childhood, and the problem is solved by a composition for an infant and/or child for improving memory ability in later childhood, wherein the composition contains | 2022-09-15 |
20220288139 | SOFT CAPSULE CONTAINING TYNDALIZED BACTERIA IN FILM - The present invention relates to a soft capsule comprising tyndalized bacteria in a film. The soft capsule, according to the present invention, can secure homogeneity of the tyndalized bacteria in the film even with a trace amount of the tyndalized bacteria, and since functional ingredients and the tyndalized bacteria can be administered simultaneously, the advantages due to the functional ingredients and the advantages due to the tyndalized bacteria can be obtained simultaneously. | 2022-09-15 |
20220288140 | FERMENTED MILK FOR IMPROVING AUTONOMIC NERVOUS FUNCTION - A fermented milk for improving autonomic nervous function containing at least one lactic acid bacterial species of the genus | 2022-09-15 |
20220288141 | GENERATION OF NEURONS BY REPROGRAMMING OF OLIGODENDROCYTES AND OLIGODENDROCYTE PRECURSOR CELLS - The invention relates to products and methods for transdifferentiating oligodendrocytes and/or oligodendrocyte precursor cells to neurons. The invention further relates to methods of treating central nervous system disorders and conditions. | 2022-09-15 |
20220288142 | RECOMBINANT ONCOLYTIC VIRUS, SYNTHETIC DNA SEQUENCE, AND APPLICATION THEREOF - A recombinant oncolytic virus, a synthetic DNA sequence and applications of the virus are described. The recombinant oncolytic virus includes a genome and an exogenous DNA sequence inserted in the genome. The exogenous DNA sequence adapts to express a basic peptide fragment, to increase the environmental pH in a host infected by the recombinant oncolytic virus. More than 60% of amino acids in the basic peptide fragment are basic amino acids. The recombinant oncolytic virus and the synthetic DNA sequence of the disclosure are used to prepare an anti-tumor drug. | 2022-09-15 |
20220288143 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING VACCINIA VIRUS AND GRANULOPOIESIS INHIBITOR AS ACTIVE INGREDIENTS - The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising a vaccinia virus and a granulopoiesis inhibitor as active ingredients. The pharmaceutical composition for treating cancer, comprising a vaccinia virus and a granulopoiesis inhibitor as active ingredients, of the present invention has a excellent anticancer effect and safety compared to the case of administering only the vaccinia virus. Therefore, the pharmaceutical composition comprising a vaccinia virus and a granulopoiesis inhibitor as active ingredients of the present invention may be efficiently utilized in treating cancer. | 2022-09-15 |
20220288144 | COMPOSITION FOR INHIBITING REDUCTION OF TESTOSTERONE AND/OR DIHYDROTESTOSTERONE - Provided is the composition capable of effectively exerting an effect on a change in a hormone balance. A composition for inhibiting the decrease in endogenous testosterone and/or dihydrotestosterone, the composition comprising Cordyceps militaris derived from Samia cynthia ricini and/or its extract is prepared. | 2022-09-15 |
20220288145 | EXTRACTS OF COPRINUS COMATUS AND THEIR USE FOR REGULATING THE PILOSEBACEOUS UNIT IN A HUMAN - Suggested is an extract of | 2022-09-15 |
20220288146 | PLANT EXOSOMES USED FOR TREATMENT OF DISEASES ORIGINATING FROM PROTEIN AGGREGATES FORMED IN CELLS - Plant exosomes can be used to reduce the protein aggregates formed in the cells and the damage they cause to the cells. Plant exosomes are of plant origin and not transgenic, and thus, they are reliable as an alternative to the drugs used in the treatment of neurodegenerative diseases, particularly ALS. Moreover, compared to the conventional applications, plant exosomes can provide a product with high efficacy and no side effects which can be produced in high amounts and at affordable prices due to the fact that it is plant-derived. | 2022-09-15 |
20220288147 | GINSENG COMPOSITION AND USE THEREOF AS A MEDICAMENT - The invention pertains to a composition, a kit and preparation thereof. The invention also pertains to the composition for use as a medical or therapeutic substance. The composition comprises a rare ginsenoside, a ginsan and a gintonin. Preferably, the ratio of ginsan to gintonin is at least 500:1 and at most 1:100. Preferably, the ratio of rare ginsenosides to ginsan and gintonin is at least 250:1 and at most 1:40. | 2022-09-15 |
20220288148 | METHODS FOR RELIEVING BACK PAIN WITH TERMINALIA CHEBULA COMPOSITIONS - Methods of relieving back pain with | 2022-09-15 |
20220288149 | SENSITIZATION CREAM COMPRISING L-ARGININE AND L-CITRULLINE AND THERAPEUTIC USES THEREOF - Topical compositions comprising L-arginine and L-citrulline are described. Methods and uses are also provided that include the administration of an effective amount of the topical compositions. The topical compositions are useful for increasing sensitization of the skin and/or for increasing blood flow to the skin. | 2022-09-15 |
20220288150 | PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOF - Disclosed herein are plant messenger packs (PMPs) encapsulating one or more exogenous polypeptides. Also disclosed are methods of producing a PMP comprising an exogenous polypeptide. | 2022-09-15 |
20220288151 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES - The present invention relates to a method for treating a neurological disease in a subject including administering to the subject a pharmaceutical composition of a eukaryotic elongation factor 2 kinase (eEF2K)-inhibiting compound. | 2022-09-15 |
20220288152 | WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES - Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5. | 2022-09-15 |
20220288153 | Methods for Treating HCV - The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof. | 2022-09-15 |
20220288154 | GNRH ANTAGONISTS FOR THE TREATMENT OF ESTROGEN-DEPENDENT DISORDERS - The present disclosure provides compositions and methods for treating estrogen-dependent disorders, such as disorders of the female reproductive system, including uterine fibroids and endometriosis, among others. Compounds described herein that may be used to treat such indications include gonadotropin-releasing hormone (GnRH) antagonists. Suitable GnRH antagonists useful in conjunction with the compositions and methods described herein include thieno[3,4d]pyrimidine derivatives, such as 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4d]pyrimidine-5-carboxylic acid and the choline salt thereof, among others. Using the compositions and methods described herein, GnRH antagonists may be periodically administered to a patient, such as one or more times per day, week, or month, over the course of an extended treatment period, such as a treatment period having a duration of multiple years. Advantageously, using the compositions and methods of the present disclosure, the GnRH antagonist may be administered to a patient over a lengthy treatment period without inducing adverse side effects, such as a loss in bone mineral density, which is otherwise known to be a risk associated with GnRH antagonism. | 2022-09-15 |
20220288155 | CXCR4 INHIBITOR FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND VIRAL INFECTIONS - A method of treating acute respiratory distress syndrome. The method comprising administering to a subject in need thereof a therapeutically effective amount of a CXCR4 inhibitor. | 2022-09-15 |
20220288156 | TREATMENT - The invention relates to the prevention or treatment of a vascular condition or heart failure. It relates to the medical use of an αvβ3- and/or αvβ5-integrin targeting agent for such a purpose. | 2022-09-15 |
20220288157 | SMALL MOLECULE SUPPRESSORS OF APOE GENE EXPRESSION AND CEREBRAL VASCULAR AMYLOID PATHOLOGY - The present disclosure provides methods of inhibiting amyloid synthesis in a subject using small molecule inhibitors. The invention also includes methods of treating disease associated with amyloid synthesis, such as Alzheimer's disease. The small molecule inhibitors disclosed herein are compounds which are non-immunosuppressant cyclosporin including the pharmaceutically acceptable salts thereof. | 2022-09-15 |
20220288158 | NOVEL ENTERIC COMBINATION THERAPY - There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome (IBD), diverticulitis, traveler's diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux esophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinson's disease, MS, Alzheimer's Disease, Motor Neuron Disease or autism, the composition comprising: (i) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, am inoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-clostridial agent selected from the above combined with an opioid blocking agent. There is also disclosed herein a method of treating various gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, traveler's diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinson's disease, MS, Alzheimer's Disease, Motor Neuron Disease or autism, the method comprising administering orally, via enema or by suppository: (i) a composition of the invention; (ii) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, am inoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (iii) at least one anti-clostridial agent selected from the above and an opioid blocking agent to a patient in need of such treatment. | 2022-09-15 |
20220288159 | AD36E4ORF1: A THERAPEUTIC TREATMENT FOR ALZHEIMER'S DISEASE - Embodiments of the present disclosure pertain to methods of treating or preventing Alzheimer's disease or symptoms of Alzheimer's disease in a subject by administering to the subject an active agent that includes an adenovirus-36 E4orf1 protein, a nucleic acid encoding an adenovirus-36 E4orfl protein, or combinations thereof. Additional embodiments of the present disclosure pertain to the active agents of the present disclosure for use in the treatment or prevention of Alzheimer's disease or symptoms of Alzheimer's disease. | 2022-09-15 |
20220288160 | FUSION PROTEINS AND USES THEREOF - A fusion protein is provided which comprises a first and a second peptide. The first peptide enables the fusion protein to bind to a receptor expressed on a cell, and the second peptide having a cleavage site that enables the fusion protein to kill said cell. The fusion protein is thus useful for the prevention or treatment of an infection caused by a pathogen. Nucleic acids encoding the fusion protein and methods of making and using the fusion protein are also provided. | 2022-09-15 |
20220288161 | TSG6 POLYPEPTIDE FRAGMENT FOR DRY EYE DISEASE - The present invention relates to the treatment of dry eye disease and particularly, although not exclusively, to the treatment of dry eye disease with a LINK_TSG6 polypeptide. | 2022-09-15 |
20220288162 | PROCESS AND COMPOSITION MATTER OF NANOPARTICLE FORMULATION FOR SYSTEMIC TREATMENT OF SEPSIS - The present invention generally relates to a process of nanoparticle formulations and its composition matter for systemic treatment of sepsis. In particular, this invention discloses a method for preparing tannic acid-ferric nanoparticles, optionally incorporating a component of vitamin D | 2022-09-15 |
20220288163 | CYTOKINE MODULATION - The inventions relate to the use of hemichannel blockers to modulate cytokine levels in a subject, including the angiogenic cytokine, VEGF, and their production, secretion and/or release, and to the use of hemichannel blockers to reduce or level cytokine activity, including in conditions characterized in whole or in part by angiogenesis and/or vessel leak. | 2022-09-15 |
20220288164 | METHOD TO INCREASE SYSTEMIC BLOOD PRESSURE IN SHOCK - Provided herein are methods of stabilizing blood pressure in severe sepsis/septic shock and other types of distributive shock using TRPV1 agonists. Also provided are pharmaceutical formulations for increasing blood pressure in septic shock the formulation including at least one TRPV1 agonist in a dosage form for parenteral administration, wherein the TRPV1 agonist is selected from capsaicin, daphane TRPV1 agonists, vanillotoxin, N-oleoyl dopamine, N-arachidonyl dopamine, BrP-LPA, and derivatives and analogues thereof. Also provided are TRPV1 agonists co-lyophilized with adrenergic agonists and/or angiotensins in a dosage form for reconstitution and parenteral administration. | 2022-09-15 |
20220288165 | NOVEL COMPOSITION COMPRISING ANTIBODIES - An aqueous solution composition of pH in the range 4.0-8.5 comprising: an antibody construct comprising an Fc domain; optionally one or more buffers being substances having at least one ionisable group with a pKa in the range 3.0 to 9.5 and which pKa is within 2 pH units of the pH of the composition; optionally one or more neutral amino acids; and an uncharged tonicity modifier; wherein the buffers are present in the composition at a total concentration of 0-5 mM; and wherein the total ionic strength of the composition excluding the contribution of the engineered protein construct is less than 20 mM. | 2022-09-15 |
20220288166 | MICROVASCULAR BLOOD FLOW DECREASING AGENT AND USE THEREOF - The purpose of the present invention is to provide a novel medicinal agent that has an effect of decreasing a microvascular blood flow. Provided is a microvascular blood flow decreasing agent that contains an immune checkpoint inhibitor. | 2022-09-15 |
20220288167 | A STABLE LYOPHILIZED FORMULATION FOR HYBRID FC FUSED G-CSF - A formulation including a stable lyophilized formulation prepared by lyophilizing an aqueous preparation and the lyophilized composition is reconstituted before use is disclosed. The formulation is suitable for administration via a subcutaneous (SC) route and contains an Fc fused to granulocyte colony stimulating factor (G-CSF) molecules via peptide bond. The formulation also contains a stabilizer, surfactant, and buffer, at pH value of the formulation that is between 3.8 and 5.2. | 2022-09-15 |
20220288168 | LONG ACTING AMYLIN RECEPTOR AGONISTS AND USES THEREOF - The present disclosure relates to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity and/or chronic weight management, dyslipidemia and/or NASH. The disclosure relates to compounds that agonize the amylin receptor and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity, and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions. | 2022-09-15 |
20220288169 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF HYPOGLYCEMIC COMPLICATIONS - This invention is directed to compositions and methods for the treatment and prevention of hypoglycemic complications. Specifically, aspects of the invention are drawn to the use of leptin for the treatment and prevention of hypoglycemic complications. | 2022-09-15 |
20220288170 | METHODS AND COMPOSITIONS FOR TREATING MUSCLE DISEASE AND DISORDERS - The present disclosure provides a method of treating muscle myopathy, including muscle dystrophies and cardiomyopathies, by administering stable, long-lasting vasoactive intestinal peptide therapeutic agents. These agents include one or more elastin-like peptides and can be administered at a low-dose. | 2022-09-15 |
20220288171 | TROPOELASTIN FOR USE IN TREATMENT OF ACNE SCARRING - The present disclosure provides methods for the treatment of an acne scar to improve color and/or appearance, and/or reduce depth, affected area, and/or volume of the acne scar. Such methods may comprise comprise administering a composition that comprises tropoelastin to an area of skin having the acne scar and optionally disrupting the fibrotic strands underneath the acne scar and administering the composition underneath the acne scar. | 2022-09-15 |
20220288172 | PROHEMOSTATIC PROTEINS FOR THE TREATMENT OF BLEEDING - Described are recombinant FXa polypeptides that can be used as antidotes to completely or partially reverse an anti-coagulant effect of a coagulation inhibitor in a subject, preferably a direct factor Xa inhibitor. Disclosed herein are recombinant factor Xa proteins and a method of completely or partially reversing an anti-coagulant effect of a coagulation inhibitor in a subject. | 2022-09-15 |
20220288173 | COMPLEX OF BOTULINUM NEUROTOXIN E AND ITS BINDING PROTEIN AS A FORMULATION WITH ENHANCED POTENCY - Compositions comprising the L complex or the M complex of the botulinum neurotoxin E with its associated neurotoxin binding protein(s) (NBP), methods of making, and methods of use to treat pain and wrinkles by injecting locally. Methods of making and isolating the L and M complex comprise a multi-step process of: providing a bacterial cultured media comprising the complex of botulinum neurotoxin E and neurotoxin binding proteins; centrifuging and pelletizing the cultured media; stirring the pelletized culture at 0 to 10° C. over a period of 4 to 24 hours; centrifuging the stirred solution to obtain a supernatant; precipitating the supernatant and filtering to obtain the precipitate; and dissolving the precipitate, centrifuging and filtering to obtain a solution comprising M complex and/or L complex of botulinum neurotoxin E and its NBP; and passing the solution through a functionalized sephadex ion exchange column to isolate the complex. | 2022-09-15 |
20220288174 | IMMUNOLOGICALLY ACTIVE FRAGMENTS OF TOXOPLASMA GONDII - proteins MIC1 and MIC4 are components of excretory/secretory antigens (ESA) that elicit delayed type hypersensitivity (DTH) responses in infected animals. These antigens are capable of inducing IFN-g secretion by splenic T cells (ELISPOT assay), stimulating T cells to produce cytokines that recruit inflammatory monocytes and neutrophils resulting in a positive luminol test (luminol ear assay), and eliciting a positive skin test in the guinea pig. | 2022-09-15 |
20220288175 | COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES TO EIMERIA OR LIMITING EIMERIA INFECTION - Vaccine vectors and methods of using the vaccine vectors to enhance the immune response to an Apicomplexan parasite and reduce the morbidity or mortality associated with subsequent infection are provided herein. The vaccine vectors include a polynucleotide encoding a Rhomboid polypeptide and optionally include an immune-stimulatory polypeptide suitably expressed on the surface of the vaccine vector. | 2022-09-15 |
20220288176 | CIRCULAR RNA MODIFICATION AND METHODS OF USE - Provided herein are methods of generating a recombinant circular RNA molecule that comprises at least one N6-methyladenosine (m | 2022-09-15 |
20220288177 | PRODUCTION OF MHC II/CII COMPLEXES - The present invention relates to in situ glycosylated MHC II/CII peptide complexes, i.e., complexes naturally glycosylated during recombinant protein expression in the host cell. The invention further relates to methods of producing glycosylated MHC II/CII peptide complexes in mammalian cells. Furthermore the invention relates to the use of such post-translationally modified, preferably glycosylated MHC II/CII complexed for use in treating rheumatoid arthritis, preferably in humans. | 2022-09-15 |
20220288178 | EPITOPES - The present invention relates to epitopes containing homocitrulline (Hcit) that can be used as targets for cancer immunotherapy. The homocitrullinated T cell epitope has (i) a predicted binding score to MHC class II or class I of <30 using the online IEDB prediction program (http://www.iedb.org/) and (ii) at least 5 consecutive amino acids that form a spiral conformational structure. These modified peptides can be used as vaccines or as targets for T cell receptor (TCR) and adoptive T cell transfer therapies. | 2022-09-15 |
20220288179 | IMMUNOGENIC PEPTIDES WITH NEW OXIDOREDUCTASE MOTIFS - The invention relates to immunogenic peptides comprising T-cell epitopes and oxidoreductase motifs with increased activity, and their use in regulating the immune response in subjects. | 2022-09-15 |
20220288180 | ANTIGEN-SPECIFIC T CELL RECEPTORS AND T CELL EPITOPES - The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy. | 2022-09-15 |
20220288181 | ANTIVIRAL VACCINES USING SPHERICAL NUCLEIC ACIDS - Spherical Nucleic Acids (SNAs) are chemically well-defined nanoscale architectures comprised of nucleic acids densely arranged around a spherical nanoparticle core in a highly oriented fashion. SNAs are highly modular structures produced by chemical synthesis and programmed assembly, allowing for their rapid modification to incorporate novel viral antigens. The present disclosure provides a SNA comprising (a) a nanoparticle core; (b) a shell of oligonucleotides attached to the external surface of the nanoparticle core, the shell of oligonucleotides comprising one or more immunostimulatory oligonucleotides; and (c) a viral antigen encapsulated in the nanoparticle core. | 2022-09-15 |
20220288182 | BACILLUS CALMETTE-GUERIN (BCG) AND ANTIGEN PRESENTING CELLS FOR TREATMENT OF BLADDER CANCER - Combination therapeutics for the treatment of cancer include the use of immune effector cells, IL-15 based superagonists and one or more immunotherapeutic agents such as | 2022-09-15 |
20220288183 | VACCINE CONSTRUCTS AND USES THEREOF AGAINST STAPHYLOCOCCUS INFECTIONS - There is provided a fusion construct of formula (I): X-A-linker-B-Z (I) wherein: (1) A and B are identical or different and are independently: (a) a polypeptide comprising a SACOL0029 polypeptide as set forth in any one of the sequences depicted in FIG. | 2022-09-15 |
20220288184 | VIRAL VECTOR - The invention concerns a novel viral vector with modified viral capsid or viral envelope; a pharmaceutical composition or immunogenic agent or vaccine comprising same; a target cell transformed or transfected with same; a combination therapeutic comprising same; use of same in treatment of cancer, and a method of treating cancer using same. | 2022-09-15 |
20220288185 | CHIKUNGUNYA VACCINE FORMULATIONS - The present invention is related to novel liquid and lyophilized formulations of Chikungunya virus useful as vaccines and methods for their preparation. | 2022-09-15 |
20220288186 | VACCINE AGAINST RSV - The present invention relates to novel nucleic acid molecules encoding a pre-fusion RSV F protein or immunologically active part thereof, wherein the pre-fusion RSV F protein comprises the amino acid sequence of SEQ ID NO: 1 or 2. The invention further relates to the use of the nucleic acid molecules, or vectors comprising said nucleic acid molecules, as a vaccine against respiratory syncytial virus (RSV). | 2022-09-15 |
20220288187 | BIODEGRADABLE NANOCOMPLEX VACCINES, METHODS FOR SUPPRESSION OF HEPAPITIS B VIRUS REPLICATION AND HEPAPITIS B VIRUS SURFACE ANTIGEN SECRETION - A hepatitis B virus (HBV) vaccine includes an HBV core antigen (HBcAg) and/or HBV surface antigen (HBsAg) formulated in nanocomplexes. The nanocomplexes contain chitosan and γ-PGA. These nanocomplexes containing HBc/sAg, chitosan, and γ-PGA can induce more balanced T helper cells (Th1 and Th2) polarization than can a conventional vaccine with an alum adjuvant. HBc/s-NC of the invention can elicit high levels of antibodies against HBsAg, a rapid elimination of HBsAg, and a slow decrease of HBeAg, indicating a phenomenon of HBsAg seroconversion. Thus, HBc/s-NC can overcome immune tolerance caused by chronic HBV infection to re-establish host immunity leading a functional cure. | 2022-09-15 |
20220288188 | NOVEL ADENOVIRAL VECTOR SYSTEM FOR GENE DELIVERY - Disclosed herein a unique cell line system to generate a novel bovine adenovirus vector that provides more gene insertion capabilities and better immunogenicity for inserted antigens. The unique cell line is used for generating and growing of the new adenovirus vectors for gene delivery or recombinant vaccine production. | 2022-09-15 |
20220288189 | INFLUENZA HEMAGGLUTININ PROTEINS AND METHODS OF USE THEREOF - In some embodiments the present invention provides influenza hemagglutinin (“HA”) polypeptides, proteins, and protein complexes that comprise a stalk domain that is engineered to facilitate maintenance of its native trimeric conformation, even if the head domain of the HA protein is removed or disrupted. In some embodiments, the present invention provides compositions comprising such polypeptides, proteins, and protein complexes, and methods of use of such proteins and compositions, for example as vaccine immunogens. | 2022-09-15 |
20220288190 | PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE - The present invention relates to a process for preparing immunogenic compositions. More particularly, it relates to a process for preparing liquid compositions of Protein D polypeptide and their use in preparing immunogenic compositions comprising Protein D polypeptide which may be used in the treatment or prevention of an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in a subject, e.g. human. | 2022-09-15 |
20220288191 | SIV AND HIV VACCINATION USING RHCMV- AND HCMV-BASED VACCINE VECTORS - Particular aspects provide for use of the β-herpesvirus Cytomegalovirus (CMV: e.g., RhCMV and HCMV) as a uniquely evolved “vector” for safely initiating and indefinitely maintaining high level cellular and humoral immune responses (against, e.g., HIV, SIV, TB, etc.). Particular aspects provide a method for treatment or prevention of, e.g., HIV, SIV or TB, comprising infection of a subject in need thereof with at least one recombinant CMV-based vector (e.g., HCMV or RhCMV) comprising an expressible HIV/SIV/TB antigen or a variant or fusion protein thereof. In particular embodiments of the method, infection is of an to immunocompetent, HCMV or RhCMV seropositive subject. Additional aspects provide for RhCMV- and HCMV-based vaccine vectors, and versions thereof with suicide or safety means. Further aspects provide pharmaceutical compositions comprising the inventive CMV-based vaccine vectors. | 2022-09-15 |
20220288192 | METHOD FOR VACCINATING AVIANS AGAINST REOVIRUS - The present invention relates to a method vaccinating avian against reovirus. | 2022-09-15 |
20220288193 | HYPERIMMUNIZED EGG PRODUCT FOR TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION - In one aspect, the present disclosure is directed to a method for preventing or treating a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmunized egg product obtained from an egg-producing animal, thereby preventing or treating coronavirus infection in the subject, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to the coronavirus. The present disclosure is also directed to hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen selected from i) a spike (S) protein, an S1 subunit protein, an S2 subunit protein, a receptor binding domain (RBD), and an immunogenic fragment thereof; ii) a nucleocapsid (N) protein, and an immunogenic fragment thereof; iii) a human ACE2 receptor protein, and an immunogenic fragment thereof; and iv) a human coronavirus selected from the group consisting of SARS-CoV, MERS-CoV, SARS-CoV-2, HCoV-HKU1, HCoV-NL63, HCoV-OC43 and HCoV-229E. Methods of preparing the hyperimmunized eggs and egg products are also disclosed. | 2022-09-15 |
20220288194 | RECOMBINANT POLYPEPTIDES CONTAINING AT LEAST ONE IMMUNOGENIC FRAGMENT AND USES THEREOF - Provided is a recombinant polypeptide containing at least one immunogenic fragment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike glycoprotein, and pharmaceutical compositions containing the same. | 2022-09-15 |
20220288195 | HEPATITIS B VIRUS VACCINES - The present disclosure relates to isolated polynucleotides and polypeptides, and related hepatitis B virus (HBV)vaccines. The present disclosure also relates to viral vectors for expressing such polypeptides, and which may be used in HBV vaccines, as well as methods of protecting a subject from HBV infection and methods of treating HBV in a subject comprising administering the polypeptides, vectors, or vaccines described herein. Methods of designing and producing an HBV vaccine comprising designing vaccine antigens to cover the diversity within a geographic area using an antigen amino acid sequence that efficiently covers the epitopes in the HBV genotypes present in the geographic area are also provided herein. | 2022-09-15 |
20220288196 | METHODS OF ORAL IMMUNOTHERAPY - The present disclosure relates to improved oral immunotherapy methods for treating food allergies, and particularly peanut allergy. Biomarkers, such as a level of peanut-specific IgE and/or peanut-specific IgG4s are used by the methods described herein. Such methods include a method of treating a subject for a peanut allergy, methods of assessing the suitability of a treatment for a peanut allergy, a method of evaluating a symptom in a subject during the course of treatment of a peanut allergy, a method of monitoring treatment for a peanut allergy in a subject, a method of reducing the risk or incidence of an adverse event in a subject receiving treatment for a peanut allergy, a method of adjusting a dose of an allergenic peanut composition, and a method of assessing a likelihood of an allergic reaction that requires administration of epinephrine to a subject receiving treatment for a peanut allergy. | 2022-09-15 |
20220288197 | METHODS OF TREATING A SUBJECT WITH A CDC42-SPECIFIC INHIBITOR - Embodiments disclosed herein relate to methods for prolonging or regulating aspects of a subject's life or immunizing a subject. In particular, methods are provided for increasing or regulating longevity, survival time, life span, and health span comprising, administering to a subject in need of treatment an effective amount of at least one Cdc42-specific inhibitor. Additionally, methods are provided for immunizing a subject comprising, administering to a subject in need of immunization an effective amount of at least one Cdc42-specific inhibitor and administering to said subject one or more immunization dosages. Methods are described that further comprise identifying a subject as one that will benefit from increased longevity, increased survival time, increased life span, increased health span, or immunization. The subject is identified on the basis of the subject's age, the subject's present medical condition, the subject's present medical treatment, or the subject's Cdc42 activity. | 2022-09-15 |
20220288198 | METHODS OF INCREASING VACCINE EFFICACY - The present invention relates, in part, to compositions and methods for enhancement of an immune response and for increased vaccine efficacy by stimulation of the TLR5 receptor, for example, with a recombinant TLR5 agonist (e.g., a flagellin-based agent or variant thereof). | 2022-09-15 |
20220288199 | Therapeutic RNA and Anti-PD1 Antibodies for Advanced Stage Solid Tumor Cancers - This disclosure relates to the field of therapeutic RNAs for treatment of subjects that have failed, or become intolerant, resistant, or refractory to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy, including innate and acquired PD-1 and/or PD-L1 therapy, as well as in subjects with advanced-stage, unresectable, or metastatic solid tumor cancers with or without failure, intolerance, resistance, or refraction to an anti-programmed cell death 1 (PD-1) or anti-programmed cell death 1 ligand 1 (PD-L1) therapy. | 2022-09-15 |
20220288200 | MULTISPECIFIC AND MULTIFUNCTIONAL MOLECULES AND USES THEREOF - Multispecific molecules that include i) a tumor-targeting moiety; and one, two or all of: (ii) an immune cell engager (e.g., chosen from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager); (iii) a cytokine molecule; and/or (iv) a stromal modifying moiety are disclosed. Additionally disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, and methods of treating a cancer using the aforesaid molecules. | 2022-09-15 |
20220288201 | COMBINATION THERAPY FOR TREATING RAS-MUTANT CANCERS - RAS mutation driven tumors are difficult to treat, with no targeted agents advancing to late stage clinical trials. Although immunotherapy is indicated for RAS mutant tumors, methods are needed to sensitize tumors to immunotherapy or to treat resistance to immunotherapy. Disclosed herein is a method for treating a RAS mutant cancer in a subject that involves administering to the subject a therapeutically effective amount of a BRAF inhibitor (BRAFi) in combination with immunotherapy, such as a checkpoint inhibitor. Also disclosed herein is a composition comprising a BRAFi and a checkpoint inhibitor in a pharmaceutically acceptable carrier. As disclosed herein, selective BRAF inhibition paradoxically prevents the growth of RAS mutant tumor cell lines in vitro with a consistent ERK hyperactivation and increased senescence. | 2022-09-15 |
20220288202 | Use of Calcineurin Inhibitor Free CTLA4-IG + Anti-IL6/IL6R For Long Term Immunosuppression in Solid Organ Transplant Recipients - The present invention provides for methods and uses of (i) an IL-6 inhibitor or IL-6R inhibitor, or both; and (ii) CT-LA-4 or CTLA-4 fusion proteins for immunosuppression and/or immunomodulation in a solid organ transplant recipient. Various embodiments of the method comprise administering an IL-6 inhibitor or IL-6R inhibitor, or both to the recipient; and administering a or CTLA-4 fusion protein such as CTLA4-Ig to the recipient and may further include administration or use of a calcineurin inhibitor. | 2022-09-15 |
20220288203 | ANTI-PODOCALYXIN ANTIBODIES AND METHODS OF USING THE SAME - The present invention is directed to anti-podocalyxin antibodies, compositions comprising the same, and methods of using such antibodies and compositions for the prevention, diagnosis and treatment of cancer. | 2022-09-15 |
20220288204 | DOSAGE AND ADMINISTRATION OF ANTI-ERBB3 (HER3) MONOCLONAL ANTIBODIES TO TREAT TUMORS ASSOCIATED WITH NEUREGULIN 1 (NRG1) GENE FUSIONS - Provided are methods for the clinical treatment of tumors associated with NRG1 gene fusions using anti-ERBB3 antibodies. | 2022-09-15 |
20220288205 | HOMEOPATHIC COMPLEX - The present invention is directed to a homeopathic complex for use in the treatment of various diseases or disorders, including use as an anti-infective agent and/or in the regeneration of diseased or damaged tissue. Ideally, the anti-infective homeopathic complex of the invention may comprise a homeopathic tincture or dilutions thereof of Hepar sulphuris calcareum or other similar profiled Calcarea or Sulphur salt or acid, | 2022-09-15 |
20220288206 | NANOPARTICLES FOR THE TREATMENT OF CANCER BY RADIOFREQUENCY RADIATION - The present disclosure relates to a method for treating tumours. In particular, the invention relates to a new therapeutic use of nanoparticles as a sensitiser agent to radiofrequency radiation. More particularly, the invention relates to the use of nanoparticles in combination with radiofrequency radiations for the treatment of tumours, the radiofrequencies inducing hyperthermia of said tumour comprising the nanoparticles in the patient. | 2022-09-15 |
20220288207 | PHOTO INDUCED CONTROL OF PROTEIN DESTRUCTION - By hijacking endogenous E3 ligase to degrade protein targets via the ubiquitin-proteasome system, PROTACs (PRoteolysis TArgeting Chimeras) provide a new strategy to inhibit protein targets that were previously regarded as undruggable. The compounds described herein comprise a photolabile group on PROTACs, enabling the degradation of protein targets in a spatiotemporally controlled manner By adding a photolabile caging group on ubiquitin recruiting moieties, light-inducible protein degradation was acheived. These opto-PROTACs display no activity in the dark, while restricted degradation can be induced at a specific time and rate by UVA-irradiation. Accordingly, these compounds provide light-controlled PROTACs and methods of using such compounds. | 2022-09-15 |
20220288208 | CETUXIMAB-IR700 CONJUGATE COMPOSITIONS - Provided are conjugates of the phthalocyanine dye IR700 and an EGFR-binding antibody, such as a cetuximab antibody, and pharmaceutical compositions thereof. In some aspects, the compositions contain an EGFR-binding antibody, such as a cetuximab antibody, that is modified by conjugation to the IR700 dye at specific positions within the heavy chain and/or the light chain of the cetuximab antibody. In some aspects, such conjugates are capable of targeted cell killing following irradiation of the conjugate Also provided are related methods of manufacture and methods of use and uses, including in treatments for tumors and specific-cancer indications. | 2022-09-15 |
20220288209 | METHOD FOR INDUCING TUMOR REGRESSION - Methods for treating cancer and/or inducing tumor regression in mammals (e.g., humans) by increasing the metabolism of the mammal, administering a BA dye to the mammal, and thereafter exposing the tumor to actinic light for activation of the BA dye. | 2022-09-15 |
20220288210 | PHOTOSENSITIZING ANTIBODY-FLUOROPHORE CONJUGATES - The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm | 2022-09-15 |
20220288211 | DOSAGE-INDICATING TOPICAL FORMULATION AND METHOD OF USING A DOSAGE-INDICATING TOPICAL FORMULATION - A dosage-indicating topical formulation and a method of using said formulation is described. The topical formulation includes one or more bioactive substances and a topical dosage indicator. The topical dosage indicator includes one or more colored copper-containing compounds, and has a color that changes as the topical dosage indicator is absorbed into the skin. The copper-containing compound may include, for example, a copper (II) salt or a copper (I) salt; and a complexation agent containing donor atoms acting as ligands, where the donor atoms are selected from the group consisting of one or more of a nitrogen (N) atom, an oxygen (O) atom, a sulfur (S) atom. The method of using the dosage indicating topical formulation includes repeated rubbing portions of the topical formulation into the skin until the change in color indicates that the skin is saturated with the formulation. | 2022-09-15 |
20220288212 | FULLERENE PHOSPHONATE GALLOYLS AND METHODS - A nanoparticle composition of buckminsterfullerene bonded with epicatechin or a galloyl functional group such as in epigallocatechin gallate, or in tannic acid, is provided that is anti-microbial and efficacious to maintain or re-establish benign healthy cellular homeostasis. In addition, the ability to penetrate hydrophobic malignant microbes via desulfurization is promoted with the addition of phosphonate pendant groups. This further enables the composition to prevent or to treat chronic obstructive pulmonary disorder (COPD), to penetrate fungal spores, and to penetrate the hydrophobic regions of uncontrolled invasive pathological bacteria. The composition can be produced at low temperatures through reactive shear milling. Delivery methods include ingestion, topical application, topical buccal application, inhalation, or injection when used as a medicament or as a food supplement. | 2022-09-15 |
20220288213 | INSULIN ANALOGUES WITH GLUCOSE REGULATED CONFORMATIONAL SWITCH - The present invention relates to glucose-responsive insulin analogues, compositions including the glucose-responsive insulin analogues, and methods of lowering blood sugar of a patient using the insulin analogue or compositions thereof. | 2022-09-15 |
20220288214 | CONJUGATES AND METHODS FOR TREATING ACROMEGALY - Provided herein are certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. He conjugates are useful to treat certain diseases, such as acromegaly. | 2022-09-15 |
20220288215 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM - Compositions and methods for increasing efficiency of cardiac metabolism are provided. | 2022-09-15 |
20220288216 | TARGETED DENDRIMER CONJUGATES - Provided herein are dendrimer-targeting agent conjugates comprising a dendrimer, the dendrimer comprising a core unit and lysine or lysine analogue building units, a HER2 targeting agent which is a peptidic moiety having a molecular weight of up to about 80 kDa and comprising an antigen-binding site, which is covalently linked by a spacer group, and a therapeutic agent which is covalently linked to a surface building unit of the dendrimer. Also provided herein are compositions comprising the conjugates, and therapeutic methods using the conjugates, particularly for treating cancer. | 2022-09-15 |
20220288217 | ASH1L INHIBITORS AND METHODS OF TREATMENT THEREWITH - Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L. | 2022-09-15 |